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Abstract
Background: In recipients with HCV/HIV coinfection, the impact that the wider use of
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direct-acting antivirals (DAAs) has had on post-liver transplant (LT) outcomes has not
been evaluated. We investigated the impact of DAAs introduction on post-LT outcome
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in patients with HCV/HIV coinfection.
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Organ Sharing data, we compared post-LT outcomes in patients with HCV and/or HIV

Methods: Using Organ Procurement and Transplant Network/United Network for
pre- and post-DAAs introduction. We categorized these patients into two eras: preDAA (2008-2012 [pre-DAA era]) and post-DAA (2014–2019 [post-DAA era]). To study
the impact of DAAs introduction, inverse probability of treatment weighting was used
to adjust patient characteristics.
Results: A total of 17 215 LT recipients were eligible for this study (HCV/HIV [n = 160];
HIV mono-infection [n = 188]; HCV mono-infection [n = 16 867]). HCV/HIV coinfection and HCV mono-infection had a significantly lower hazard of 1- and 3-year graft
loss post-DAA, compared pre-DAA (1-year: adjusted hazard ratio [aHR] 0.29, 95% confidence interval (CI) 0.16–0.53 in HIV/HCV, aHR 0.58, 95% CI 0.54–0.63, respectively;
3-year: aHR 0.30, 95% CI 0.14–0.61, aHR 0.64, 95% CI 0.58–0.70, respectively). The
hazards of 1- and 3-year graft loss post-DAA in HIV mono-infection were comparable to those in pre-DAA. HCV/HIV coinfection had significantly lower patient mortality
post-DAA, compared to pre-DAA (1-year: aHR 0.30, 95% CI 0.17–0.55; 3-year: aHR
0.31, 95% CI 0.15–0.63).
Conclusions: Post-LT outcomes in patients with coinfection significantly improved and
became comparable to those with HCV mono-infection after introducing DAA therapy.
The introduction of DAAs supports the use of LT in the setting of HCV/HIV coinfection.
KEYWORDS

direct-acting antivirals, hepatitis C virus, human immunodeficiency virus, liver transplantation,
posttransplant outcome

Abbreviations: aHR, adjusted hazard ratio; AIDS, acquired immune deficiency syndrome; cART, combination antiretroviral therapy; DAAs, direct-acting antivirals; DCD, donation after circulatory
death; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INSTIs, integrase strand transfer inhibitors; IPTW, inverse probability of treatment weighting; LT, liver transplantation; MELD,
model for end-stage liver disease; OPTN, Organ Procurement and Transplant Network; SVR, sustained virological response; UNOS, United Network for Organ Sharing; US, United States
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INTRODUCTION

effects of DAA introduction might be different between patients with
HCV mono-infection and patients with HCV/HIV coinfection. The aim

Liver transplantation (LT) for patients with human immunodeficiency

of this study is to investigate possible different impact of DAAs on

virus (HIV) was initially considered a contraindication due to high mor-

post-LT outcomes in patients with HCV/HIV coinfection compared

tality from acquired immune deficiency syndrome (AIDS).1 Neverthe-

to those with HCV mono-infection. To study these aims, possible

less, the number of LTs for patients with HIV has been increasing. Prior

improvements in cART during the study period should be acknowl-

to 1996, anti-HIV drugs such as HIV reverse transcriptase inhibitors

edged, which might have synergetic effects with DAA and further

were used that were less potent and well tolerated.2 The introduction

improve post-transplant outcomes in patients with HCV/HIV coinfec-

of the protease inhibitor in the mid-1990s allowed the use of highly

tion. To address possible confounding effects of recent improvement in

effective combination antiretroviral therapy (cART), which was key in

HIV therapies, post-transplant outcomes were compared between the

HIV.2,3

following three groups: HCV/HIV coinfection, HCV mono-infection,

treating HIV and improving life expectancy of those living with

In the current era cART is very potent at maintaining virologic suppres-

and HIV mono-infection.

sion and is associated with near normal life expectancy in those living
with HIV.4 In line with these change, post-LT outcomes in these patients

2

have also improved.5

MATERIALS AND METHODS

In the United States about 20% of people living with HIV have
either evidence of past or current hepatitis C virus (HCV) infection,

2.1

Patient

although this does vary substantially depending on the risk group such
as intravenous drug users.6,7 Infection with both HIV and HCV is called

We analyzed the Organ Procurement and Transplantation Net-

HIV/HCV coinfection, according to the Centers for Disease Control

work/United Network for Organ Sharing (OPTN/UNOS) Standard

and Prevention.8 In general, HIV coinfection worsens the general sur-

Transplant and Research files for LT from January 1, 2008, to Decem-

vival in patients with HCV because the HIV leads to rapid progres-

ber 31, 2019. Patients 18 years or older at LT and patients with HCV

sion of hepatitis, increases the risk of viral persistence, and accelerates

and/or HIV were included for this study.

the development of cirrhosis and hepatocellular carcinoma (HCC) than

Patients who had diagnosis code(s) of 4104 (acute hepatic necrosis

in HCV mono-infected patients.9–11 Compared to patients with HCV

[AHN]: type C), 4106 (AHN: type B and C), 4204 (cirrhosis type C), 4206

mono-infection, the risk of progression to end stage liver disease is six-

(cirrhosis: type B and C), and/or 4593 (hepatitis C: chronic or acute)

coinfection.12

Post-LT sur-

were classified as HCV infection. Patients with HIV positive serostatus

vival rates were significantly lower in recipients with HCV/HIV coin-

were classified as HIV infection. Patients who were re-transplanted or

fection than in HCV mono-infection due to a higher incidence of severe

had transplants combined with other organs were excluded (Figure 1).

fold more rapid in patients with HCV/HIV

forms of recurrence of HCV such as fibrosing cholestatic hepatitis and

The study period was classified into two eras to assess possible

the rapid progression of fibrosis.5,13 While only strictly selected recipi-

impact of DAAs on post-LT outcomes in recipients with HCV/HIV

ents with HCV/HIV coinfection could showed similar post-LT outcome

coinfection: a pre-DAA era (pre-DAA), which included patients trans-

to the US LT recipients, post-LT graft survival in overall recipients with

planted from January 1, 2008 to December 31, 2012, and a post-DAA

HCV/HIV coinfection was worse than those in recipients with HCV

era (post-DAA), which included patients transplanted from January 1,

mono-infection according to US multicenter trial.14

2014 to December 31, 2019. To allow a washout period of the effect

Emerging direct-acting antivirals (DAAs) regimens, introduced in

of DAAs, patients transplanted in 2013 were excluded because DAAs

late 2013, have dramatically changed the outcome and care in patients

became available in 2013.21 Patients were censored on the last day of

infection.15,16

Before 2013, interferon and ribavirin-based

each era (December 31, 2012, in the pre-DAA or December 31, 2019,

treatment regimens were mainly used for patients with HCV, which

in the post-DAA, respectively) in the post-LT outcome analysis to elim-

had limited efficacy and debilitating side effects, making them con-

inate impact on DAA on post-LT outcomes of patients in the pre-DAA.

traindicated in patients with decompensated cirrhosis.17 DAAs have

Continuous covariates included age, model for end stage liver disease

a remarkably high sustained virological response (SVR) rate 12 weeks

(MELD) score, serum albumin, and cold ischemia time. Gender, mod-

after treatment completion, resulting in significant reductions in mor-

erate/severe ascites, encephalopathy, life support requirement, por-

with HCV

HCV.15

DAAs have been used for LT candidates

tal vein thrombosis, donation after circulatory death (DCD) donor,

and recipients with HCV, which successfully prevent post-LT recur-

and donor HCV status were considered as binary variables. Categori-

rence of HCV.18,19 While the safety and efficacy of DAAs for LT patients

cal variables included Karnofsky score (10-30%, 40%–60%, and 70%–

with HCV mono-infection is well reported and has been associated

100%), MELD (MELD-Na) score (6–29, 30–34, 35 or higher), serum

with improvements in post-LT outcomes,18–20

the impact of DAA intro-

albumin value (<3.0 mg/dl, 3.0–3.9 mg/dl, and 4.0 mg/dl or higher), and

duction on post-LT outcomes in recipients with HCV/HIV coinfection

cold ischemia time (<6 h, 6–7.9 h, and 8h or higher). The categorized

remains to be elucidated.

recipient and donor age (<30 years old [yo], 30–39 yo, 40–49 yo, 50–

bidity in patients with

We hypothesized that DAA introduction would dramatically

59 yo, 60–69 yo, 70 yo, or higher) were used for inverse probability of

improve the post-LT outcomes in not only patients with HCV mono-

treatment weighting (IPTW) estimation. This study was approved for

infection but also patients with HCV/HIV coinfection, and that the

an institutional review board (IRB) waiver after IRB review.
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FIGURE 1

2.2

Flow chart of study population selection

Outcome of interest

The variables used to calculate the IPTW are shown in Table 1. The
probability of a subject to be assigned into post-DAA, defined as p,

The study evaluated the impact of DAA therapy on post-LT outcomes,

was estimated using logistic regression with post-DAA regressed on

which might be influenced by infection status. Within each era, we clas-

observed baseline characteristics such as age, gender, liver laboratory

sified patients into three infection status categories: HCV, HIV mono-

results, and donor information before LT. Each subject’s weight was cal-

infection, and HIV/HCV coinfection. One- and three-year graft loss and

culated as 1/p if the subject was in the post-DAA or 1/(1-p) if subject

patient mortality were compared between eras in each infection status

was in pre-DAA. If there were no significant differences between the

group.

two eras after adjusting for IPTW, the two populations were balanced,
or post-DAA selection bias was controlled. To estimate the risk of viral
infection and DAAs induction, multivariable Cox regression with IPTW
was used. A p-value < .05 was considered significance. All variables or

2.3

Statistical analysis

variable-by-DAAs interactions with p-value < .05 were retained in the
final multivariable model; estimated adjusted hazard ratios (aHR) were

Descriptive analyses, for example, continuous variables were shown

illustrated. All statistical analyses were completed using SPSS version

as median with interquartile range, categorical discrete variables were

27 (IBM, Chicago, USA), R version 3.5.1 (R Foundation for Statistical

shown as percentage. The Mann–Whitney U test for continuous vari-

Computing, Vienna Austria), and SAS 9.4 (SAS Institute, Cary NC, USA).

ables and chi-square were used to test the population difference
between the pre- and post-DAA. Kaplan–Meier curve analysis was
used for posttransplant survival and compared by log-rank tests. For

3

RESULTS

risk analyses, we used the IPTW score-a weighted propensity-score
approach22 for the entire population to adjust for characteristic differ-

3.1

Study population and patient characteristics

ences between the era (pre-DAA) without and with the introduction of
DAAs (post-DAA). We used standardized mean difference to examine

Between January 1, 2008 and December 31, 2019, 21 116 adult

the balance of each covariate between two ears before and after IPTW.

patients with HCV and/or HIV received LT. Patients combined with
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Comparisons of patient characteristics in pre- and post-DAA eras and adjustment by inverse probability of treatment weighting

Patients group (infectious status),
n (%)

Age (year) group, n (%)

Group

Pre-DAA
n = 8575

Post-DAA
n = 8640

p
Crude

HCV/HIV

63 (0.7)

97 (1.1)

<.001

0.082

0.0

HIV mono

46 (0.5)

142 (1.6)

<.001

0.587

0.0

.006

0.041

0.011

<.001

0.336

0.030

HCV mono

8466 (98.7)

8401 (97.2)

<30

35 (0.4)

27 (0.3)

30–<40

106 (1.2)

106 (1.2)

40–<50

1004 (11.7)

486 (5.6)

50–<60

5008 (58.4)

3197 (37.0)

60–<70

2250 (26.2)

4538 (52.5)

70 or higher

172 (2.0)

286 (3.3)

Gender, n (%)

Male

6270 (73.1)

6475 (74.9)

Female

2305 (26.9)

2165 (25.1)

Serum albumin (mg/dl) group, n
(%)

<3.0

4269 (49.8)

2998 (34.7)

≥3.0, < 4.0

3430 (40.0)

4042 (46.8)

≥4.0

876 (10.2)

1600 (18.5)

SMD
Unweighted

SMD
Weighted

Grade 3/4 encephalopathy, n (%)

850 (9.9)

598 (6.9)

<.001

−0.107

−0.068

Moderate/severe ascites, n (%)

2405 (28.0)

1823 (21.1)

<.001

−0.161

−0.013

1740 (20.3)

1390 (16.1)

<.001

0.153

0.027

<.001

0.129

0.081

<.001

0.199

0.0

<.001

0.165

0.186

.63

0.007

0.026

<.001

0.238

0.0

Karnofsky score, n (%)

MELD score group, n (%)

Serum sodium group (mEq/L), n
(%)

10%-30%
40%–60%

3100 (36.2)

3701 (42.8)

70%–100%

3735 (43.5)

3549 (41.1)

6–29

6966 (81.2)

7329 (84.8)

30–34

676 (7.9)

449 (5.2)

35+

933 (10.9)

862 (10.0)

<135

2953 (34.4)

2172 (25.1)

135–144

5401 (63.0)

6234 (72.2)

145 or higher

221 (2.6)

234 (2.7)

794 (9.3)

1259 (14.6)

Portal vein thrombosis, n (%)
Life support requirement, n (%)
Cold ischemia time (hours) group,
n (%)

363 (4.2)

353 (4.1)

<6

3611 (42.1)

4511 (52.2)

≥6, < 8

2578 (30.1)

2538 (29.4)

≥8

2386 (27.8)

1591 (18.4)

DCD graft, n (%)

Yes

486 (5.7)

622 (7.2)

<.001

0.062

0.051

Donor age (year) group, n (%)

<30

2578 (30.1)

2268 (26.2)

<.001

0.215

0.0

30–<40

1317 (15.3)

1739 (20.1)

40–<50

1853 (21.6)

1589 (18.4)

50–<60

1849 (21.6)

1794 (20.8)

.16

0.021

0.043

Donor gender, n (%)

60–<70

799 (9.3)

982 (11.4)

70 or higher

179 (2.1)

268 (3.1)

Male

5108 (59.6)

5237 (60.6)

Female

3467 (40.4)

3403 (39.4)

Abbreviations: DAA, direct-acting antivirals; DCD, donation after circulatory death; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MELD, model
for end-stage liver disease; SMD, standardized mean difference.
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other organs (n = 1650), re-transplants (n = 645), and transplants in

and 3-year graft loss in patients received LT in the post-DAA were not

2013 (n = 1933) were excluded. The remaining 17 215 patients were

significantly different from those in the pre-DAA in patients with HIV

eligible for this study. Patients were divided into two groups; patients

mono-infection. Similar trends were observed when comparing 1-year

received LT in the pre-DAA (n = 8575) and those in the post-DAA

patient mortality between eras in each viral status (Figure 2B). In terms

(n = 8640) (Figure 1). Patient characteristics are shown in Table 1. The

of causes of death within 3-year after LT in patients with HCV/HIV

rates of patients with HCV/HIV coinfection undergoing LT increased

coinfection, no graft failure due to recurrence of HCV was found in

from 0.7% in pre-DAA to 1.1% in post-DAA. The rates of patients

the post-DAA (45.0% pre-DAA vs. 0% post-DAA, p = .01). AIDS-related

with HIV mono-infection undergoing LT increased from 0.5% to 1.6%

death within 3-year after LT was 15.4% in the post-DAA while it was 0%

(p < .001).

in the pre-DAA (p = .29) (Table 4). In patients with HCV mono-infection,

There were significant differences in patient characteristics

there were 19 cases of graft failure within 3-year after LT due to recur-

between pre- and post-DAA (Table 1). Compared with patients that

rence of HCV in the post-DAA while there were 342 cases of graft fail-

underwent LT in pre-DAA, the proportions of DCD LT were signif-

ure due to recurrence of HCV in the pre-DAA (19.3% vs. 1.8%, p < .001)

icantly higher post-DAA (5.7%–7.2%, p < .001). The proportions

(Table S2).

of patients with Grade 3/4 encephalopathy (9.9%–6.9%, p < .001),
moderate/severe ascites (28.0%–21.1%, p < .001), and Karnofsky
score 10%–30% (20.3%–16.1%, p < .001) were significantly lower in
the post-DAA.

3.4
The risks of graft loss and patient mortality
stratified by the viral infectious status in each era
In the pre-DAA, the adjusted risks for 1- and 3-year graft loss in

3.2
Patient characteristics in each viral status
pre- versus post-DAA

patients with HCV/HIV coinfection were significantly higher than
those with HCV mono-infection (1-year: aHR 2.79, 95% CI 1.94–3.98,
3-year: aHR 2.48, 95% CI 1.80–3.40) or HIV mono-infection (1-year:

Comparison of patient characteristics in each viral status between pre-

aHR 4.05, 95% CI 1.97–8.32, 3-year: aHR 2.76, 95% CI 1.59–4.78)

and post-DAA are shown in Tables 2 and 3 and Table S1. In patients

(Figure 3A). In the post-DAA, no statistically significant difference was

with HCV/HIV coinfection, patients received an LT in the post-DAA had

observed in the risk of 1- and 3-year graft loss between the groups

lower proportions of patients with serum sodium group <135 mEq/L

(Figure 3B). Figures S1 and S2 show graft survival curves for these viral

(42.9% vs. 24.7%, p = .02), and a higher proportion of liver graft receipt

infection groups in each era.

from HCV-antibody positive donors (9.5% vs. 23.7%, p = .02). The

Similarly, in the pre-DAA, the adjusted risks of 1-year and 3-year

annual number of HCV/HIV coinfection cases was similar between the

patient mortality in patients with HCV/HIV coinfection were signifi-

two eras (median: 12 cases/year in pre-DAA versus 14 cases/year in

cantly higher than those with HCV mono-infection (1-year: aHR 2.60,

post-DAA, p = .31) (Table 2). In patients with HIV mono-infection, the

95% CI 1.82–3.72, 3-year: aHR 2.36, 95% CI 1.72–3.23) or HIV mono-

annual number of cases with HIV mono-infection per year was signif-

infection (1-year: aHR 4.72, 95% CI 2.26–9.87, 3-year: aHR 2.62, 95%

icantly higher in post-DAA (median: nine cases/year in pre-DAA ver-

CI 1.56–4.39) (Figure 3C). In the post-DAA, no statistically significant

sus 16 cases/year in post-DAA, p = .006) (Table S1). Patients with HCV

difference was observed in the risk of 1-year and 3-year patient mortal-

mono-infection received LT in the post-DAA had significantly lower

ity among each viral status (Figure 3D). Figures S3 and S4 show patient

proportions of patients with grade ¾ encephalopathy (9.9% vs. 6.9%,

survival curves for these viral infection groups in each era.

p < .001), moderate/severe ascites (28.1% vs. 21.2%, p < .001), Karnofsky score 10%–30% (20.3% vs. 16.0%, p < .001) compared with patients
who received LT in the pre-DAA. There was no significant difference in

4

DISCUSSION

the annual number of cases with HCV mono-infection (median: 1689
cases vs. 1410 cases, p = .27) (Table 3).

This study revealed that post-LT outcomes in patients with coinfection significantly improved and became comparable to those with HCV
mono-infection after introducing DAA therapy. Post-LT outcomes in

3.3
The risks of graft loss and patient mortality
between each era in viral infectious status

patients with HCV/HIV coinfection have become equivalent to those
with HCV or HIV mono-infection in the post-DAA era. Because of the
significantly worse post-LT outcomes in this particular population, indi-

The populations were balanced after adjusting for IPTW (Table 1). The

cations of LT for patients with HIV/HCV coinfection needed to be more

risks of graft loss in patients who received LT in the post-DAA were

carefully assessed. The findings in this study indicate that, after DAAs

significantly lower in patients with HCV/HIV coinfection and HCV

introduction, patients who have end stage liver disease associated with

mono-infection (HCV/HIV coinfection; 1-year: aHR 0.29, 95% confi-

HCV/HIV coinfection could be considered as LT candidates similarly to

dence interval (CI) 0.16–0.53, 3-year: aHR 0.30, 95% CI 0.14–0.61,

those with HCV or HIV mono-infection.

HCV mono-infection; 1-year: aHR 0.58, 95% CI 0.54–0.63, 3-year: aHR

The risks of post-LT patient mortality and graft loss were signif-

0.64, 95% CI 0.58–0.70 [ref. pre-DAA]) (Figure 2A). The risks of 1-year

icantly lower in the post-DAA era in patients with coinfection and
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Comparisons of characteristics of patients with HCV/HIV coinfection between eras

Group

Pre-DAA

Post-DAA

n = 63

n = 97

p-Value

Annual number of cases, median (IQR)

12 (9, 16)

14 (12, 20)

.31

Age (year), median (IQR)

54.0 (49.5, 57.0)

57.0 (52.0, 62.0)

.001

48 (76.2)

72 (74.2)

.93

Gender, n (%)

Male
Female

15 (23.8)

25 (25.8)

Serum albumin (mg/dl) group, n (%)

<3.0

28 (44.4)

31 (32.0)

≥3.0, <4.0

20 (31.7)

45 (46.4)

15 (23.8)

21 (21.6)

5 (7.9)

6 (6.2)

.91

≥4.0
Grade 3/4 encephalopathy, n (%)
Moderate/severe ascites, n (%)
Karnofsky score, n (%)

.16

15 (23.8)

12 (12.4)

.09

10%–30%

9 (14.3)

15 (15.5)

.19

40%–60%

23 (36.5)

48 (49.5)

70%–100%

31 (49.2)

34 (35.0)

6–29

51 (81.0)

80 (82.5)

30–34

5 (7.9)

6 (6.2)

35+

7 (11.1)

11 (11.3)

<135

27 (42.9)

24 (24.7)

135–144

36 (57.1)

69 (71.1)

145 or higher

0 (0)

4 (4.1)

Portal vein thrombosis, n (%)

6 (9.5)

10 (10.3)

Life support requirement, n (%)

1 (1.6)

3 (3.1)

.94

<6

31 (49.2)

44 (45.4)

.38

≥6, <8

21 (33.3)

27 (27.8)

≥8

11 (17.5)

26 (26.8)

4 (6.3)

7 (7.2)

MELD score group, n (%)

Serum sodium group (mEq/L), n (%)

Cold ischemia time (hours) group, n (%)

DCD graft, n (%)
Donor age (year), median (IQR)
Donor gender, n (%)

.91

.02

1.00

1.00

42.0 (27.5, 53.0)

38.0 (29.0, 52.0)

.76

Male

34 (54.0)

59 (60.8)

.49

Female

29 (46.0)

38 (39.2)

6 (9.5)

23 (23.7)

Donor HCV, n (%)

.02

Note: Data were summarized using the median with IQR for continuous variables and using percentage for discrete variables. Continuous variables were
analyzed using the Mann–Whitney U test, and discrete variables were analyzed using a chi-square test.
Abbreviations: DAA, direct-acting antivirals; DCD, donation after circulatory death; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR,
interquartile range; MELD, model for end-stage liver disease.

HCV mono-infection. Due to differences in the patient characteristics

in HCV/HIV coinfection group, compared to HCV mono-infection

between the pre- and post-DAA eras, IPTW was used to adjust for pos-

group.

sible confounding effects to evaluate causal impacts of DAAs on the

According to the previous report, which investigated LT-recipients

post-LT outcomes. IPTW is a causal inference method developed to

with HIV infection, HCV recurrence as cause of death has decreased

emulate randomized controlled studies using observational data.23,24

in HCV mono-infected patients, but not in HCV/HIV coinfected

After the risk adjustment, in patients with HCV mono-infection, the

patients.25 Meanwhile, there was no graft failure due to recurrence

risk of graft loss and patient mortality were approximately 50% lower

of HCV for the cause of death in the post-DAA era in the HCV/HIV

in the post-DAA era, whereas the risk of graft loss and patient mor-

coinfection group in our study, despite contributing to nearly half of

tality were 70% lower in patients with HCV/HIV coinfection. Patients

all graft losses in the pre-DAA era. Similarly, a significant decrease

with HIV mono-infection did not show significant improvements in

in the HCV mono-infection group was noted. These effects are likely

posttransplant outcomes, especially in 3-year patient and graft sur-

related to the introduction of DAA therapy. Possible reasons for the

vival. The findings from those comparisons between 3 groups further

worse post-LT outcomes in patients with coinfection might be associ-

supported our hypothesis that DAA had different prognostic effects

ated with HIV status and control. Recently, simplified regimens that
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TA B L E 3

Comparisons of characteristics of patients with HCV mono-infection between eras

Group

Pre-DAA

Post-DAA

n = 8466

n = 8401

p-Value

Annual number of cases, median (IQR)

1689 (1666, 1692)

1410 (1216, 1645)

Age (year), median (IQR)

56.0 (52.0, 60.0)

60.0 (56.0, 64.0)

6184 (73.0)

6290 (74.9)

Gender, n (%)

Male
Female

2282 (27.0)

2111 (25.1)

Serum albumin (mg/dl) group, n (%)

<3.0

4222 (49.9)

2911 (34.6)

≥3.0, <4.0

3386 (40.0)

3940 (46.9)

≥4.0
Grade 3/4 encephalopathy, n (%)

MELD score group, n (%)

Serum sodium group (mEq/L), n (%)

1550 (18.5)
577 (6.9)

.007

<.001

<.001

2381 (28.1)

1780 (21.2)

<.001

10%–30%

1718 (20.3)

1345 (16.0)

<.001

40%–60%

3058 (36.1)

3592 (42.8)

Moderate/severe ascites, n (%)
Karnofsky score, n (%)

858 (10.1)
835 (9.9)

.27
<.001

70%–100%

3690 (43.6)

3464 (41.2)

6–29

6881 (81.3)

7142 (85.0)

30–34

667 (7.9)

428 (5.1)

35+

918 (10.8)

831 (9.9)

<135

2914 (34.4)

2110 (25.1)

135–144

5337 (63.1)

6067 (72.2)

145 or higher

215 (2.5)

224 (2.7)

<.001

<.001

<.001

Portal vein thrombosis, n (%)

782 (9.2)

1221 (14.5)

Life support requirement, n (%)

357 (4.2)

336 (4.0)

<6

3565 (42.1)

4383 (52.2)

≥6, <8

2544 (30.0)

2475 (29.5)

≥8

2357 (27.8)

1543 (18.3)

480 (5.7)

604 (7.2)

<.001

42.0 (27.0, 53.0)

42.0 (29.0, 54.0)

<.001

5050 (59.7)

5090 (60.6)

Cold ischemia time (hours) group, n (%)

DCD graft, n (%)
Donor age (year), median (IQR)
Donor gender, n (%)

Male
Female

Donor HCV, n (%)

3416 (40.3)

3311 (39.4)

638 (7.5)

1431 (17.0)

.50
<.001

.22

<.001

Note: Data were summarized using the median with IQR for continuous variables and using percentage for discrete variables. Continuous variables were
analyzed using the Mann–Whitney U test, and discrete variables were analyzed using a chi-square test.
Abbreviations: DAA, direct-acting antivirals; DCD, donation after circulatory death; HCV, hepatitis C virus; IQR, interquartile range; MELD, model for endstage liver disease.

TA B L E 4

Comparisons of the causes of death after liver transplantation in patients with HCV/HIV coinfection between eras
1-year

3-years

Pre-DAA
n = 13

Post-DAA
n=8

p-value

Pre-DAA
n = 20

Post-DAA
n = 13

p-value

Graft failure due to recurrence of HCV, n (%)

5 (38.5)

0 (0)

.14

9 (45.0)

0 (0)

.01

AIDS-related, n (%)

0 (0)

0 (0)

–

0 (0)

2 (15.4)

.29

Malignancy, n (%)

0 (0)

2 (25.0)

.26

1 (5.0)

3 (23.1)

.31

Infection, n (%)

5 (38.5)

3 (37.5)

1.00

6 (30.0)

3 (23.1)

.97

Others, n (%)

3 (23.0)

3 (37.5)

.83

4 (20.0)

5 (38.5)

.45

Abbreviations: AIDS, acquired immune deficiency syndrome; DAA, direct-acting antivirals; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

8 of 11

SHIMADA ET AL .

F I G U R E 2 Adjusted hazards of graft loss and mortality in patients transplanted in post-direct-acting antiviral (DAA) (ref. Pre-DAA) among
each viral infectious status. (A) 1-year and 3-year graft loss. (B) 1-year and 3-year mortality. Hepatitis C virus (HCV)(+)/human immunodeficiency
virus (HIV)(+), HCV/HIV coinfection; HCV(+)/HIV(−), HCV mono-infection; HCV(−)/HIV(+), HIV mono-infection

can enhance medication compliance and lower drug toxicities with

status and each era. Cotter et al. compared the risks for graft failure

newer cART have been observed, which might have contributed to

after LT by Cox regression model using OPTN/UNOS file according to

the greater improvement in posttransplant outcomes of patients with

the infectious status in pre- and post-DAA era, separately.28 However,

HCV/HIV coinfection.26 To examine these possible effects of cART, we

they did not compare the risk between pre- and post-DAA era, because

compared the post-LT outcomes in patients with HIV mono-infection.

of possible confounders between eras (e.g., improved medical care, LT

However, there was no difference in their risks of graft loss between

recipient selection changes). In our study, a comparison of risk between

eras. These results may suggest that the outcome improvements in

pre- and post-DAA era in each infection type was evaluated. To reduce

HIV/HCV coinfection patients would be independent of cART. When

the impact of confounders and significant changes in patient charac-

patients with coinfection developed liver graft dysfunction due to post-

teristics between pre- and post-DAA eras, risk analyses for graft loss

LT HCV recurrence, they were unlikely to have received cART appro-

were performed after controlling possible characteristics differences

priately, potentially leading to a further deterioration in their clini-

between the era using IPTW approach. Recipient and donor charac-

cal condition secondary to uncontrolled HIV. It is speculated that bet-

teristics were successfully controlled after the matching. These results

ter control of HCV status by DAA therapy may have allowed suffi-

further supported the different impact of DAA on posttransplant out-

cient and timely cART post-LT, leading to more significant improve-

come between patient with HCV/HIV coinfection and with HCV mono-

ments in the outcomes of patients with HIV/HCV coinfection in the

infection. Although HCV/HIV coinfection represents a rare indication

post-DAA era.

for LT, individual transplant centers are unlikely to have sufficient expe-

HCV/HIV coinfection was a well-known risk factor for graft loss and

rience to allow an investigation of the risks and benefits of LT for this

mortality after LT.27 This study corroborates this elevated risk for mor-

population. Consequently, the historically poor post-LT outcomes may

tality and graft loss compared to recipients with HIV or HCV mono-

raise concerns when considering LT in these patients.5,13 However,

infection. After the wider use of DAAs, the outcomes in patients with

based on those findings, it should be acknowledged that this particular

coinfection have become similar to the other two groups. Two recent

patient population can achieve satisfactory post-LT outcomes. While

papers reported that HCV/HIV coinfected LT-recipient outcomes have

the number of LT patients with HCV mono-infection has decreased, 1.2

significantly improved, and HCV coinfection was not associated with

million people are infected with HIV in the USA, and about 25% of peo-

graft failure among HIV infected LT recipients in post-DAA era.28,29

ple with HIV in the United States also have HCV. There will be occa-

Our study showed same results after control for characteristic differ-

sions for transplant practitioners in which LT needs to be considered

ences between the era and also compared by both each viral infectious

to those with coinfection. This study thus provides essential insights
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F I G U R E 3 Adjusted hazards of graft loss and mortality in patient’s viral infectious status in pre- and post-direct-acting antiviral (DAA). (A)
Graft loss in pre-DAA. (B) Graft loss in post-DAA. (C) Patient mortality in pre-DAA. (D) Patient mortality in post-DAA. Hepatitis C virus
(HCV)(+)/human immunodeficiency virus (HIV)(+), HCV/HIV coinfection; HCV(+)/HIV(-), HCV mono-infection; HCV(−)/HIV(+), HIV
mono-infection
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into the outcomes after LT for patients with this condition to improve
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not to undergo antiviral therapy before transplant.33 In the same consensus statement, pre-LT HCV antiviral therapies have been recommended for patients with coinfection to prevent liver disease progression and decompensation while awaiting an LT.33 Of note, antiHIV medications for cART have interactions with many drugs such
as immunosuppressants, interferon, and DAAs.34 The combination of
cART and ribavirin has been associated with an increased risk of lactic acidemia.35 Because patients with HIV/HCV coinfection continue to
receive cART after LT, they might be better treated with DAAs before
LT to reduce the complexity and interactions in post-LT medication
regimens. When comparing the outcomes after LT in patients with
HIV mono-infection between pre- and post-DAA eras, the risks of 1year graft loss and mortality in post-DAA era tended to be lower. This
might be due to increased use of integrase strand transfer inhibitors
(INSTIs) in cART in these patients. In 2016, INSTIs were recommended
as first line regimens for cART-naïve patients by Department of Health
and Human Services guidelines.36 Hence, INSTIs are often used for
cART, recently.37 INSTIs have fewer side effects drug interactions
with anti-rejection medications and DAAs compared to older cART
regimens.38 This might give the positive impact on patients with HIV
mono-infection. Of note, the improvement was not obvious in 3-year
patient and graft outcomes. Detailed clinical information regarding
HCV and/or HIV therapies is not available in the OPTN/UNOS registry.
Future studies should therefore address the possible effects of timing
and regimens of antiviral treatments.
Limitations of this study should be acknowledged. This is a retrospective study that might contain the potential for unmeasured and
residual confounding even despite the IPTW analyses performed. Due
to the lack of information in the OPTN/UNOS registry, the actual
treatment histories for HCV and/or HIV, HCV genotype, also whether
patients received DAA treatment or not were not evaluated in this
study.
In conclusion, post-LT outcomes in patients with coinfection significantly improved and became comparable to those with HCV monoinfection after introducing DAA therapy. Because the outcomes of
patients with HCV/HIV coinfection were similar to those in patients
with HIV or HCV mono-infection after the widespread use of DAAs, LT
should be more eagerly sought as a definitive treatment for this unique
patient population.
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